Clinical trialNCT04905407TerminatedPhase 2Interventional

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

SponsorSyros PharmaceuticalsEnrollment66Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the retinoic acid receptor alpha (RARA) gene. This genetic profile is found in about 3 of every 10 people with AML. During the trial, tamibarotene will be given with 2 other drugs that are already used together to treat people who have AML and who cannot start treatment with standard chemotherapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Michael Kelly Executive Medical Director, MD
Syros Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France

Chu Lyon Sud
Pierre-Bénite, Pierre Benite, France
Chu Angers
Angers, France
Ch de la Côte Basque
Bayonne, France
Hôpital Avicenne Hématologie Clinique
Bobigny, France
Chu de Caen Normandie
Caen, France
Chu Limoges
Limoges, France
Chu de Nantes - Hôtel Dieu
Nantes, France
Hôpital L'Archet- Chu de Nice
Nice, France
Chu de Bordeaux - Hôpital Haut-Lévèque
Pessac, France
Chu de Poitiers
Poitiers, France
Hôpital Saint-Louis
Vellefaux, France
Centre Hospitalier de Versailles
Versailles, France
Institut Gustave Roussy
Villejuif, France

United States

City of Hope
Duarte, California, United States
Ucla Medical Center Division of Hematology/oncology
Los Angeles, California, United States
Sarah Cannon Research Institute at Colorado Blood Cancer Institute
Denver, Colorado, United States
University of Colorado
Denver, Colorado, United States
Hartford Healthcare
Hartford, Connecticut, United States
Northside
Atlanta, Georgia, United States
University of Mississippi
Jackson, Mississippi, United States
Hca Midwest Research Medical Center
Kansas City, Missouri, United States
Atlantic Health
Morristown, New Jersey, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Novant Health
Charlotte, North Carolina, United States
the Ohio State University James Cancer Hospital
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →TamibaroteneVenetoclax →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Aug 2021
Primary completion: 12 Aug 2024
Completion: 12 Aug 2024
Last update posted: 24 Feb 2025
Registered enrollment: 66
Registry id: NCT04905407

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.